Search results
Results from the WOW.Com Content Network
In September 2020, Sinovac began Phase I–II trials in China on children and adolescents ages 3–17. [92] In May 2021, Sinovac began Phase IIb trials in China with 500 participants for children and adolescents 3–17 years old. [93] In June 2021, it was announced that the vaccine was safe and immunogenic in this age group. [94]
Thailand Food and DrugAdministration (FDA) on Monday gave emergency use authorisationfor the COVID-19 vaccine of Sinovac Biotech, paving theway for the country's first coronavirus inoculations.
Offering Sinovac Biotech COVID-19 vaccines to the public in Singapore for the first time since Friday, several private clinics reported overwhelming demand for the Chinese-made shot, despite ...
A spokesperson for the UN agency told Reuters that the ministry will continue to communicate with COVAX facility to receive vaccines in the coming months. North Korea rejects offer of nearly 3 ...
The vaccine may have characteristics favorable for vaccinating people in the developing world. While mRNA vaccines, such as the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of +90%, mRNA vaccines present distribution challenges for some nations, as some may require deep-freeze facilities and trucks.
However, the vaccine was not authorised for use by the Health Sciences Authority (HSA). [12] [13] On 2 June 2021, MOH approved the Sinovac vaccine for used in private healthcare settings so people, who are not suitable to take the mRNA vaccines, can take the Sinovac vaccine. However, since the China-made vaccine is not part of the national ...
The World Health Organization (WHO) said on Tuesday it has approved a COVID-19 vaccine made by Sinovac Biotech for emergency use listing, paving the way for a second Chinese shot to be used in ...
On 7 December 2021, at a symposium in Brazil with its partner Instituto Butantan, Sinovac said it would update its vaccine to the new variant and make it available in three months. [100] On 2 December, the Finlay Institute was already developing a version of Soberana Plus against the variant. [101]